Kepos Capital LP Innoviva, Inc. Transaction History

Kepos Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$8.11 - $15.23 $676,771 - $1.27 Million	-83,449 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$10.28 - $14.38 $204,674 - $286,305	-19,910 Reduced 19.26%	83,449 $1.18 Million
Q3 2019 Nov 13, 2019	SELL	$10.05 - $14.55 $977,965 - $1.42 Million	-97,310 Reduced 48.49%	103,359 $1.09 Million
Q2 2019 Aug 13, 2019	SELL	$13.1 - $14.95 $708,945 - $809,064	-54,118 Reduced 21.24%	200,669 $2.92 Million
Q4 2018 Feb 13, 2019	BUY	$13.96 - $18.26 $3.56 Million - $4.65 Million	254,787 New	254,787 $4.45 Million
Q2 2018 Aug 13, 2018	SELL	$13.44 - $17.59 $682,805 - $893,642	-50,804 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$13.8 - $16.99 $701,095 - $863,159	50,804 New	50,804 $847,000

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

Stay updated on Kepos Capital LP with notifications on news.